Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes

Table 2

Difference in the use of medications according to the use of metformin.

Variable	Metformin user	Metformin nonuser	P
Sulfonylurea	312 (44.2)	48 (31.6)	0.004
DPP-4 inhibitor	279 (39.5)	36 (23.7)	0.002
Meglitinide	12 (1.7)	9 (5.9)	0.006
Thiozolidinedione	32 (4.5)	9 (5.9)	0.698
α-Glucosidase inhibitor	11 (1.6)	9 (5.9)	0.004
SGLT2 inhibitor	0	0
GLP-1 agonist	2 (0.3)	0	1.000
Rapid-acting insulin	20 (2.8)	11 (7.2)	0.008
Long-acting insulin	92 (13.0)	27 (17.8)	0.125
Premixed insulin	60 (8.5)	20 (13.16)	0.073

Values are expressed as number (%). P value for the chi-square test comparing the groups with and without metformin. DPP-4, dipeptidyl peptidase-4; SGLT2, sodium-glucose transporter protein 2; and GLP-1, glucagon-like peptide-1.